OncoOne Aims to Deliver a Pipeline of Innovative Treatments, Overcoming Mere Symptom Relief With Curative Approaches
Based on our expertise in antibody engineering, we precisely design our antibodies for the specific purpose, and we provide innovative treatments with tailored functionalities, with an established GMP-conform and efficient production process.
OncoOne is at the forefront of current approaches to advance precision medicine with site-restricted targeted therapeutics. Our discovery that oxMIF is generated exclusively in the oxidative environment at sites of inflammation provides the basis for a groundbreaking and versatile approach to direct therapeutics exclusively to diseased sites. This breakthrough fuels our commitment to harness the full potential of therapeutics.
Exploiting our expertise in selectively targeting sites of disease, we have expanded our approach to radioimmunotherapy and launched the PreTarg-it® platform to broaden the OncoOne portfolio with additional targets and further oncological indications
These innovative treatments have the potential to alter the course of the disease, not just the management of symptoms.
collaborations
Are You Interested in Investing in Future Precision Medicines?
OncoOne is seeking investors for a Series A+ / B financing and is looking for strategic partnerships to propel the development of our diverse and rich pipeline of highly differentiated new precision medicines.
OncoOne would like to explore strategic partnerships that would:
- Accelerate the clinical development of its pipeline in oncology and chronic inflammation.
- Leverage the existing expertise of its partner for selected disease areas and drug development.
OncoOne welcomes offers for:
- Global Licensing Transaction
- Strategic Alliance
- Build-to-Buy
OncoOne is open to:
- Investors for a Series A+/B financing in Q2 2024 enabling the company to take its first programs into the clinic.
- Discuss alternative investment approaches, including separate funding of its two platform technologies, Anti-oxMIF antibodies and PreTarg-it®
- Offers from Corporate Venture Funds for Early Stage strategic investment.
